FSTX F-Star Therapeutics Inc

F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022

F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) --  (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that the Company will hold a conference call and webcast on May 10th, 2022, at 9:00 a.m. EST to review first quarter 2022 financial results and provide a corporate update.

To access the call, participants may join via a live webcast on the Investors & News section of the F-star Therapeutics website, under . To join by phone, participants may dial the following numbers at least 10 minutes prior to the start of the call:

Investors dial1-877-704-4453
International investors dial1-201-389-0920
Webcast
Conference ID13728991

A replay of the conference call will be available for 90 days from the call and may be accessed in the Investor & News/ section of the F-star Therapeutics website.

About F-star Therapeutics, Inc.

F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.

For more information visit our  and follow us on  and .

For further information, please contact:

For investor inquiries:

John Fraunces

Relationship Manager



For media inquiries:

Helen Shik

Shik Communications LLC





EN
02/05/2022

Underlying

FSTXF-Star Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on F-Star Therapeutics Inc

 PRESS RELEASE
Free
FSTX F-Star Therapeu...

F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition...

F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) --  (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced that the Committee on Foreign Investment in the United States (“CFIUS”) has cleared the previously ...

March 7, 2023 1 EN
 PRESS RELEASE
Free
FSTX F-Star Therapeu...

invoX Pharma and F-star Therapeutics issue Joint Statement

invoX Pharma and F-star Therapeutics issue Joint Statement LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statement regarding their pending transaction in response to a media report: The parties continue working together in active discussions with the Committee on Foreign Investment in the United States (“CFIUS”) about the terms of a mitigation agreement to address CFIUS’s concerns regarding pot...

January 26, 2023 1 EN
 PRESS RELEASE
Free
FSTX F-Star Therapeu...

F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tet...

F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress FS222 demonstrated early antitumor activity with one complete response and six disease stabilizations in patients with advanced solid tumors CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecifics in immunotherapy so more people with cancer can live longer and improved lives, today announced new clinical ...

December 6, 2022 1 EN
 PRESS RELEASE
Free
FSTX F-Star Therapeu...

F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation T...

F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research - FS118 is Well-Tolerated Across all Dose Levels with No Serious Adverse Events Related to FS118 Therapy - Novel mechanism showing Increased Peripheral Immune Cells and LAG-3 shedding - 54.8% Disease Control Rate in PD-L1 Acquired Resistance Patients at doses > 1mg/kg, including one partial response in Anaplastic Thyroid Cancer - Further studies ongoing in Acquired Resistance Squamous Cell Carcinoma of the Head and Neck and...

November 7, 2022 1 EN
 PRESS RELEASE
Free
FSTX F-Star Therapeu...

F-star Therapeutics Reports Second Quarter 2022 Financial Results and ...

F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody TherapeuticFS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement with MS...

August 11, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch